Manager TitleAgeSince
Chief Executive Officer 62 06/01/2025
Director of Finance/CFO - 31/08/2014
Chief Operating Officer - 17/06/2024
Director TitleAgeSince
Director/Board Member - -
Director/Board Member 44 31/10/2020
Director/Board Member - -
Date Insider Type Main position Quantity % Market Cap.
04/09/20 Sell

Director

51,844 0.2510%
13/08/20 Sell

Director

2,253 0.0109%
12/08/20 Sell

Chief Financial Officer

12,003 0.0581%
Change 5-day change 1-year change 3-year change Capi.($)
-24.28%-33.67% - - 409K
+1.38%-5.42%-21.87%+7.75% 119B
-0.04%-3.83%-3.45%-6.91% 12.59B
-1.07%-2.72%+57.47%+107.00% 8.97B
-3.47%+11.33%-43.23%-67.18% 4.84B
-0.59%-9.64%0.00%+38.75% 2.65B
-0.51%-2.30%-8.89%-22.28% 1.64B
+1.24%-5.91%-22.95%-31.52% 1.61B
-3.60%-8.48%-7.26%-59.89% 1.53B
Average -3.43%+0.07%-6.27%-4.29% 19.05B
Weighted average by Cap. +0.87%-1.99%-15.70%+9.12%
Logo Endologix, Inc.
Endologix, Inc. develops, manufactures, markets and sells medical devices for the treatment of aortic disorders. The Company's products are designed for the minimally-invasive endovascular treatment of abdominal aortic aneurysms (AAA). Its AAA products are developed on one of two platforms: traditional minimally-invasive endovascular aneurysm repair (EVAR) or endovascular aneurysm sealing (EVAS), the Company's solution for sealing the aneurysm sac while maintaining blood flow. The Company's EVAR products include the AFX Endovascular AAA System (AFX System), the VELA Proximal Endograft (VELA) and the Ovation Abdominal Stent Graft System (Ovation System). The Company's EVAS product is the Nellix Endovascular Aneurysm Sealing System (the Nellix EVAS System).
Employees
-
  1. Stock Market
  2. Stocks
  3. ELGXQ Stock